The Patients With Gestational Diabetes Were Interfered With Qigong.
Launched by CHEN CHAOYANG · Jul 18, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding how Qigong, a gentle exercise that combines movement, meditation, and breathing, can help women with gestational diabetes. The main goals are to see if practicing Qigong can help control blood sugar levels and improve mood and sleep for expectant mothers dealing with this condition. Women who are between 20 and 40 years old, pregnant with a single baby, and between 24 to 28 weeks along may be eligible to participate, provided they have no serious health issues or complications.
Participants in the trial will be practicing Qigong for three months, and researchers will monitor the effects it has on their health. It's important to note that this trial is not yet recruiting participants, but it aims to provide valuable insights into how this ancient practice might support women during pregnancy when facing gestational diabetes. If you or someone you know fits the eligibility criteria and is interested in this kind of intervention, keep an eye out for when the trial starts!
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 20 years old≤ age ≤ 40 years old;
- • Those with clear awareness, acceptable reading and language expression skills, and barrier-free communication;
- • singleton pregnancy;
- • gestational age between 24 and 28 weeks, with the upper limit of gestational age set at 28 weeks at the time of inclusion to allow for at least 8 weeks of intervention;
- • Body mass index (BMI) is lower than 40;
- • Agree to participate in this project and sign the informed consent form.
- Exclusion Criteria:
- • Those with previous GDM and diabetes;
- • Artificial insemination;
- • Those with serious obstetric complications and contraindications;
- • Participants in other planned and supervised exercise programs or researchers during the study.
About Chen Chaoyang
Chen Chaoyang is a leading clinical trial sponsor dedicated to advancing medical research and innovation. With a focus on developing safe and effective therapeutic solutions, the organization collaborates with various stakeholders, including research institutions and healthcare providers, to conduct rigorous clinical trials across multiple therapeutic areas. Chen Chaoyang prioritizes ethical practices, regulatory compliance, and patient safety, ensuring that all trials are designed and executed with the highest standards of scientific integrity. Through its commitment to excellence, the sponsor aims to contribute significantly to the improvement of global health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Li Jie, Doctor
Principal Investigator
Shanghai University of Traditional Chinese Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported